Becton Dickinson, BioMedomics to Release Rapid Covid-19 Detection Test
March 31 2020 - 4:02PM
Dow Jones News
By Kimberly Chin
Becton Dickinson & Co. and BioMedomics said Tuesday they
will launch a new test that can detect current or past exposure to
Covid-19, the illness caused by the new coronavirus, in nearly 15
minutes, part of a new wave of companies seeking to scale up
testing and cut down wait times for results.
Clinical-diagnostics company BioMedomics has developed and
manufactured the new test, which will be available through Becton
Dickinson. The test will be exclusively distributed by Henry Schein
Inc. Healthcare providers around the U.S. will be able to receive
the tests.
The four-stage test won't require special equipment, the
companies said. It can be used in a laboratory or at a
point-of-care facility.
The test will be able to detect antibodies in the blood that are
produced in response to the coronavirus infection. The test can
detect past exposure as well, which could help researchers pinpoint
more precisely the occurrence of the infection in the
population.
Though the test has been clinically validated at some hospitals
and labs in the U.S. and China, it hasn't been reviewed by the U.S.
Food and Drug Administration. However, it is permitted for
distribution and use under the fast-tracked emergency guidelines of
the agency.
Write to Kimberly Chin at kimberly.chin@wsj.com
(END) Dow Jones Newswires
March 31, 2020 16:47 ET (20:47 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Becton Dickinson (NYSE:BDX)
Historical Stock Chart
From Apr 2024 to May 2024
Becton Dickinson (NYSE:BDX)
Historical Stock Chart
From May 2023 to May 2024